Kavanagh JE, et al. - To corroborate the efficacy of mepolizumab [the first licensed anti-IL5 mAb for severe eosinophilic asthma (SEA)] in the real-world setting, researchers performed this retrospective review. They also evaluated baseline features related to response. Participants were all patients who took at least 16 weeks of therapy with mepolizumab (100mg sc) for SEA at a regional asthma centre in the UK. At each 4-weekly visit, clinical data was obtained. The patients were grouped as ‘responders’ or ‘non-responders’ at 16, 24 and 52 weeks. Experts defined a response as ≥ 50% decrease in exacerbations, or for patients needing maintenance oral corticosteroids (mOCS), ≥ 50% decrease in prednisolone dose. They defined super-responders as exacerbation-free and off mOCS at one year. Findings revealed that exacerbation frequency and mOCS needs were reduced as a result of treatment with mepolizumab in a real-world SEA cohort. Better outcomes were achieved in correlation with nasal polyposis, a lower BMI and a lower maintenance prednisolone need at baseline. In over 90% of patients, 12-month response was identifiable by week 24.